These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 2823425)

  • 1. Tissue distribution of macrophages, class II transplantation antigens, and receptors for platelet-derived growth factor in normal and rejected human kidneys.
    Fellström B; Klareskog L; Larsson E; Tufveson G; Wahlberg J; Rönnstrand L; Heldin CH; Terracio L; Rubin K
    Transplant Proc; 1987 Oct; 19(5):3625-7. PubMed ID: 2823425
    [No Abstract]   [Full Text] [Related]  

  • 2. Products of HLA class I and class II (B,C,DP,DQ,DR) genes all contribute to induction of recipient anti-donor responses in rejected kidneys.
    Bonneville M; Moreau JF; Blokland E; Pool J; Charron D; Goulmy E; Soulillou JP
    Transplant Proc; 1988 Apr; 20(2):193-5. PubMed ID: 3284038
    [No Abstract]   [Full Text] [Related]  

  • 3. Importance of PDGF receptor expression in accelerated atherosclerosis-chronic rejection.
    Fellström B; Dimeny E; Larsson E; Klareskog L; Tufveson G; Rubin K
    Transplant Proc; 1989 Aug; 21(4):3689-91. PubMed ID: 2548309
    [No Abstract]   [Full Text] [Related]  

  • 4. Expression of class II antigens in human renal allografts: comparison of acute rejection, chronic rejection, and cyclosporine nephrotoxicity.
    Toma H; Tanabe K; Oba S; Horita S; Takahashi K; Teraoka S; Ota K
    Transplant Proc; 1987 Oct; 19(5):3719-20. PubMed ID: 3313898
    [No Abstract]   [Full Text] [Related]  

  • 5. Macrophages and T lymphocytes expressing HLA-D region-encoded gene products in rejected renal transplants.
    Fellström B; Larsson E; Claesson K; Tufveson G; Wahlberg J; Klareskog L
    Transplant Proc; 1988 Jun; 20(3):372-4. PubMed ID: 3132767
    [No Abstract]   [Full Text] [Related]  

  • 6. Expression of donor and recipient class I and class II major histocompatibility complex antigens in human liver grafts.
    Steinhoff G; Wonigeit K; Happrecht J; Johnson JP; Pichlmayr R
    Transplant Proc; 1987 Oct; 19(5):3561-4. PubMed ID: 3313859
    [No Abstract]   [Full Text] [Related]  

  • 7. T lymphocyte cloning from rejected human kidney allograft. Recognition repertoire of alloreactive T cell clones.
    Bonneville M; Moreau JF; Blokland E; Pool J; Moisan JP; Goulmy E; Soulillou JP
    J Immunol; 1988 Dec; 141(12):4187-95. PubMed ID: 3058801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence that antibodies eluted from rejected kidneys of HLA-identical transplants define a non-MHC alloantigen expressed on human kidneys.
    Mathew JM; Joyce S; Lawrence W; Mohanakumar T
    Transplantation; 1991 Sep; 52(3):559-62. PubMed ID: 1897033
    [No Abstract]   [Full Text] [Related]  

  • 9. Platelet-derived growth factor receptors in the kidney--upregulated expression in inflammation.
    Fellström B; Klareskog L; Heldin CH; Larsson E; Rönnstrand L; Terracio L; Tufveson G; Wahlberg J; Rubin K
    Kidney Int; 1989 Dec; 36(6):1099-102. PubMed ID: 2557480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA class II induction and cellular infiltration are effectively suppressed by triple therapy in renal allografts.
    McWhinnie DL; Fuggle SV; Azevedo LS; Jones RM; Morris PJ
    Transplant Proc; 1987 Oct; 19(5):3628-9. PubMed ID: 3313873
    [No Abstract]   [Full Text] [Related]  

  • 11. Rapid immunodiagnosis of kidney rejection by using activation markers on kidney tubular cells and infiltrating T subset cells.
    Tötterman TH; Hanås E; Larsson E; Lindgren PG; Sjöberg O; Wahlberg J; Tufveson G
    Transplant Proc; 1987 Oct; 19(5):3570-1. PubMed ID: 3313860
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute kidney graft rejection. A morphological and immunohistological study on "zero-hour" and follow-up biopsies with special emphasis on cellular infiltrates and adhesion molecules.
    Andersen CB; Ladefoged SD; Larsen S
    APMIS; 1994 Jan; 102(1):23-37. PubMed ID: 7513171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-HLA class II antibodies in kidney retransplant patients.
    Arnold ML; Pei R; Spriewald B; Wassmuth R
    Tissue Antigens; 2005 Apr; 65(4):370-8. PubMed ID: 15787721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post transplant development of MICA and anti-HLA antibodies is associated with acute rejection episodes and renal allograft loss.
    Panigrahi A; Gupta N; Siddiqui JA; Margoob A; Bhowmik D; Guleria S; Mehra NK
    Hum Immunol; 2007 May; 68(5):362-7. PubMed ID: 17462503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperacute rejection from antibody against class II HLA antigens.
    Ghasemian SR; Light JA; Sasaki TA; Barhyte DY
    Clin Transplant; 1998 Dec; 12(6):569-71. PubMed ID: 9850452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms in organ allograft rejection. An experimental and clinical study.
    Claesson K
    Scand J Urol Nephrol Suppl; 1987; 103():1-42. PubMed ID: 3321417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vimentin antibodies: a non-HLA antibody as a potential risk factor in renal transplantation.
    Carter V; Shenton BK; Jaques B; Turner D; Talbot D; Gupta A; Chapman CE; Matthews CJ; Cavanagh G
    Transplant Proc; 2005 Mar; 37(2):654-7. PubMed ID: 15848491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoglobulin M-to-immunoglobulin G anti-human leukocyte antigen class II antibody switching in cardiac transplant recipients is associated with an increased risk of cellular rejection and coronary artery disease.
    Lietz K; John R; Burke E; Schuster M; Rogers TB; Suciu-Foca N; Mancini D; Itescu S
    Circulation; 2005 Oct; 112(16):2468-76. PubMed ID: 16230499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of HLA-specific antibodies in kidney transplant rejection: published studies and local data.
    Worthington JE; Martin S; Barker AJ; McWilliam LJ; Dyer PA
    Clin Transpl; 2006; ():349-61. PubMed ID: 18365389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expansion of humoral donor-specific alloreactivity after renal transplantation correlates with impaired graft outcome.
    Varnavidou-Nicolaidou A; Iniotaki-Theodoraki AG; Doxiadis II; Georgiou D; Patargias T; Stavropoulos-Giokas C; Kyriakides G
    Hum Immunol; 2005 Sep; 66(9):985-8. PubMed ID: 16360838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.